Ocular Therapeutix Q1 net loss $64.8M ($0.49/sh); revenue $14.8M up 10.4% YoY

OCULAR THERAPEUTIX, INC

2024-Q1 EPS reported -$0.49 revenue$14,774,000

Net loss of $64.8M ($0.49/sh) vs $30.3M loss ($0.39/sh) in Q1 2023; includes $28M non-cash loss on debt extinguishment.
Total net revenue $14.8M, up 10.4% YoY, driven by DEXTENZA product sales.
Cash and equivalents $482.9M; Feb 2024 private placement raised $325M; cash runway expected into 2028.
Phase 3 SOL-1 wet AMD trial randomization started April 2024; site activation progressing under FDA SPA.
Pravin Dugel appointed Exec Chairman, President & CEO; Investor Day set for June 13, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

OCULAR THERAPEUTIX, INC reported first quarter ended March 31, 2024 results: revenue $14.8 million, net income $(64.8) million, EPS $(0.49) per share.

Period: first quarter ended March 31, 2024
Revenue: $14.8 million
Net income: $(64.8) million
EPS: $(0.49) per share
Result: reported results

Exact text from the filing

Company believes that its current cash balance is sufficient to support its planned expenses, obligations, and capital expenditure requirements into 2028. Total net revenue was $14.8 million for the first quarter of 2024, a 10.4% increase over total net revenue of $13.4 million in the comparable period in 2023, driven by increased DEXTENZA sales. Total net revenue

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-24-058003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.